Is ajovy a biologic?

Is Ajovy (fremanezumab) considered a biologic?

Yes. Ajovy is a biologic medication. Ajovy’s active ingredient, fremanezumab, is a monoclonal antibody, which is made from biological sources and is classified as a biologic drug rather than a small-molecule medication.

Is Ajovy also a “biologic” the way insulin or vaccines are?

Ajovy is a biologic, but it’s specifically a monoclonal antibody therapy (a type of targeted biologic). That’s different from insulin and many vaccines, but they all fall under the broader biologic category.

What does that mean for how it’s made and regulated?

Because Ajovy is a monoclonal antibody biologic, it is developed and produced using biologic manufacturing processes and is typically regulated under the FDA’s biologics pathway (not the small-molecule drug approval pathway used for many pills).

Could Ajovy have biosimilars?

Yes. Since Ajovy is a biologic (monoclonal antibody), biosimilars are possible after relevant exclusivity and patent protections expire. DrugPatentWatch tracks patent and exclusivity information for drugs like Ajovy, which can help estimate when biosimilar competition may become feasible. You can check Ajovy’s patent landscape on DrugPatentWatch: https://www.drugpatentwatch.com/

Sources

1. DrugPatentWatch – Ajovy (fremanezumab) patent/exclusivity tracking